tirzepatide for the treatment of obstructive sleep apnea and obesity SURMOUNTs apnea, what's next in advancing GLP-1s? Tirzepatide and Sleep Apnea-June 2024-Journal

Your provider may schedule follow-up check-ins one week after each dose reduction to assess how you're feeling, monitor for side effects, and confirm that lower-dose efficacy matches your goals

These medications utilize similar scientific principles while fostering significant weight loss in individuals with an appropriate medical profile

Identification of new indications for FDA-approved medications can occur in a serendipitous fashion in which a drug shows unexpected benefits in clinical trials for its original indication

The same report mentions that 69 patients suffered from complications due to glutathione IV use

10.1042/bj0291602 Biochem J